Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343197 · ClinicalTrials.gov registry record · Phase 1
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03343197 is a Phase 1 study that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 49 participants.
The verdict
NCT03343197, a Phase 1 study, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.
Interventions
- DRUG AG-120
- DRUG AG881
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03343197
The ClinicalTrials.gov registry entry for NCT03343197 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AG-120 is the first listed.
NCT03343197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03343197 about?
NCT03343197 is a clinical study titled "Study of AG-120 and AG-881 in Subjects With Low Grade Glioma". Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.
What is the current status of trial NCT03343197?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-03-20. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT03343197?
The interventions under investigation include: AG-120 (DRUG), AG881 (DRUG).
Who is sponsoring clinical trial NCT03343197?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.